LOGIN  |  REGISTER
Assertio
Viking Therapeutics

Butterfly Network to Participate at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

March 06, 2024 | Last Trade: US$2.35 0.21 -8.20

NEW YORK & BURLINGTON, Mass. / Mar 06, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that Joseph DeVivo, President, Chief Executive Officer and Chairman, and Heather Getz, Executive Vice President, Chief Financial and Operations Officer, will participate in a fireside chat and host one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 13, 2024, at 8:40 am ET. The conference will be held virtually.

A webcast of the fireside chat will be available in the Events & Presentations section of the Butterfly investor website, and available for replay following the event until June 11, 2024.

To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your Oppenheimer representative.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission is to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country.

Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB